BACKGROUND: This study aims to assess the clinical outcomes of patients with spine metastases who underwent stereotactic ablative radiation therapy (SABR) as part of their treatment. SABR has arisen as a contemporary treatment option for spinal metastasis patients with good prognoses. MATERIALS AND METHODS: Between November 2010 and September 2018, Spinal SABR was performed in patients with metastatic disease in different settings: radical (SABR only), postoperative (after decompression and/or fixation surgery), and reirradiation. Local control (LC), pain control, overall survival (OS) and toxicities were reported. RESULTS: Eighty-five patients (corresponding to 96 treatments) with spine metastases were included. The median age was 59 years (range, 23-91). In most SA BR (82.3%, n = 79) was performed as the first local spine treatment, while in 12 settings (12.5%), fixation and/or decompression surgery was performed prior to SABR. Two-year overall survival rate was 74.1%, and median survival was 19 months. The LC rate at 2 years was 72.3%. With regard to pain control, among 67 patients presenting with pain before SA BR, 83.3% had a complete response, 12.1% had a partial response, and 4.6% had progression. Vertebral compression fractures occurred in 10 patients (11.7%), of which 5 cases occurred in the reirradiation setting. Radiculopathy and myelopathy were not observed. No grade III or IV toxicities were seen. CONCLUSION: This is the first study presenting a Brazilian experience with spinal SA BR, and the results confirm its feasibility and safety. SABR was shown to produce good local and pain control rates with low rates of adverse events.
BACKGROUND: This study aims to assess the clinical outcomes of patients with spine metastases who underwent stereotactic ablative radiation therapy (SABR) as part of their treatment. SABR has arisen as a contemporary treatment option for spinal metastasis patients with good prognoses. MATERIALS AND METHODS: Between November 2010 and September 2018, Spinal SABR was performed in patients with metastatic disease in different settings: radical (SABR only), postoperative (after decompression and/or fixation surgery), and reirradiation. Local control (LC), pain control, overall survival (OS) and toxicities were reported. RESULTS: Eighty-five patients (corresponding to 96 treatments) with spine metastases were included. The median age was 59 years (range, 23-91). In most SA BR (82.3%, n = 79) was performed as the first local spine treatment, while in 12 settings (12.5%), fixation and/or decompression surgery was performed prior to SABR. Two-year overall survival rate was 74.1%, and median survival was 19 months. The LC rate at 2 years was 72.3%. With regard to pain control, among 67 patients presenting with pain before SA BR, 83.3% had a complete response, 12.1% had a partial response, and 4.6% had progression. Vertebral compression fractures occurred in 10 patients (11.7%), of which 5 cases occurred in the reirradiation setting. Radiculopathy and myelopathy were not observed. No grade III or IV toxicities were seen. CONCLUSION: This is the first study presenting a Brazilian experience with spinal SA BR, and the results confirm its feasibility and safety. SABR was shown to produce good local and pain control rates with low rates of adverse events.
Authors: Brett W Cox; Daniel E Spratt; Michael Lovelock; Mark H Bilsky; Eric Lis; Samuel Ryu; Jason Sheehan; Peter C Gerszten; Eric Chang; Iris Gibbs; Scott Soltys; Arjun Sahgal; Joe Deasy; John Flickinger; Mubina Quader; Stefan Mindea; Yoshiya Yamada Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-19 Impact factor: 7.038
Authors: Edward Chow; Peter Hoskin; Gunita Mitera; Liang Zeng; Stephen Lutz; Daniel Roos; Carol Hahn; Yvette van der Linden; William Hartsell; Eshwar Kumar Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-12 Impact factor: 7.038
Authors: Balamurugan A Vellayappan; Samuel T Chao; Matthew Foote; Matthias Guckenberger; Kristin J Redmond; Eric L Chang; Nina A Mayr; Arjun Sahgal; Simon S Lo Journal: Expert Rev Anticancer Ther Date: 2018-07-03 Impact factor: 4.512
Authors: Arjun Sahgal; Lijun Ma; Vivian Weinberg; Iris C Gibbs; Sam Chao; Ung-Kyu Chang; Maria Werner-Wasik; Liliyanna Angelov; Eric L Chang; Moon-Jun Sohn; Scott G Soltys; Daniel Létourneau; Sam Ryu; Peter C Gerszten; Jack Fowler; C Shun Wong; David A Larson Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-15 Impact factor: 7.038
Authors: Shayna E Rich; Ronald Chow; Srinivas Raman; K Liang Zeng; Stephen Lutz; Henry Lam; Maurício F Silva; Edward Chow Journal: Radiother Oncol Date: 2018-02-01 Impact factor: 6.280
Authors: Michael B Bernstein; Eric L Chang; Behrang Amini; Hubert Pan; Maria Cabanillas; Xin A Wang; Pamela K Allen; Laurence D Rhines; Claudio Tatsui; Jing Li; Paul D Brown; Amol J Ghia Journal: Thyroid Date: 2016-07-25 Impact factor: 6.568
Authors: Raj Singh; Eric J Lehrer; Basem Dahshan; Joshua D Palmer; Arjun Sahgal; Peter C Gerszten; Nicholas G Zaorsky; Daniel M Trifiletti Journal: Radiother Oncol Date: 2020-02-28 Impact factor: 6.280